OBJECTIVES We sought to prospectively and randomly compare survival with clinical and
hemodynamic variables in patients with congestive heart failure (CHF) treated with standard …

Background Angiotensin converting-enzyme (ACE) inhibitors used for the treatment of heart
failure relieve symptoms, increase exercise performance, reduce hospital admissions and …

In a double-blind, randomized trial, 253 patients with heart failure (New York Heart
Association functional class IV) received either enalapril (n= 127) or placebo (n= 126) in …

Background—Angiotensin-converting enzyme (ACE) inhibitors are generally prescribed by
physicians in doses lower than the large doses that have been shown to reduce morbidity …

Background. Patients with congestive heart failure have a high mortality rate and are also
hospitalized frequently. We studied the effect of an angiotensin-converting–enzyme inhibitor …

In this study, the use of enalapril and captopril is compared in the treatment of congestive
heart failure. Although both drugs act on the renin-angiotensin system via converting …

Angiotensin converting enzyme inhibitors improve symptoms and prolong life in congestive
heart failure, but the dose in the individual patient is uncertain. A randomized, 48-week …

The renin-angiotension system is activated in many patients with congestive heart failure
(CHF), resulting in angiotensin-mediated vasoconstriction and aldosterone-mediated …

Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …

To evaluate the influence of the angiotensin-converting-enzyme inhibitor enalapril (2.5 to 40
mg per day) on the prognosis of severe congestive heart failure (New York Heart …